cannabis
Answer: Curaleaf’s ‘Calm’ strain does not reliably soothe 90% of users; the figure comes from a limited consumer survey, not from FDA-approved clinical evidence. The claim circulates in marketing, but rigorous trials are missing, leaving patients to rely on anecdote rather than data. Medical Disclaimer: This article is for
cannabis
Alzheimer caregivers often miss five cannabis-related benefits that could influence care decisions. These include modest memory support, potential anti-inflammatory effects, dosage flexibility, reduced caregiver stress, and emerging safety data, though each is clouded by regulatory gaps. 35% of marketed CBD ‘memory enhancers’ overstate clinical evidence, according to the FDA. Medical
cannabis
6 Macro Trends Cannabis Benefits vs False-Claims Fallout The lawsuit flattened net margins across five flagship products for the first time in a decade. The decision sent shockwaves through both domestic retailers and overseas distributors, forcing a rapid reassessment of pricing, compliance, and the credibility of benefit claims. Legal Disclaimer:
cannabis
Buyers should verify label accuracy, terpene profiles, dosage information, and regulatory compliance before purchasing cannabis products to avoid hidden discrepancies in therapeutic claims. Recent investigations revealed a 20% gap between advertised benefits and actual product performance, prompting tighter scrutiny of industry practices. Legal Disclaimer: This content is for informational purposes
cannabis
70% False vs Real Cannabis Benefits Exposed About 70% of advertised medical benefits of cannabis lack clinical backing; only a few claims survive rigorous peer-review. 71% of online testimonials for cannabis pain relief are unsupervised, according to Attorney General Kramer’s 2024 memorandum. This stark figure sets the tone for
cannabis
Yes, 98% of documented media testimonials in the case files indicate intentional misinformation, satisfying the intent standard under defamation law. Courts are increasingly treating those misrepresentations as actionable. The flood of litigation reflects a broader push to separate genuine cannabis benefits from corporate hype. Legal Disclaimer: This content is for
cannabis
In a 2024 FTC investigation, regulators found that Curaleaf’s claim of delivering pain relief up to 40% faster than standard analgesics is not backed by peer-reviewed evidence. The company’s advertising cites a 30-minute onset, but independent trials show only marginal benefit over placebo. Medical Disclaimer: This article is
cannabis
Audit Your Store to Claim Cannabis Benefits Legally One brick-and-mortar store trimmed its marketing team costs by 15% after a 7-step audit stopped a multimillion-dollar lawsuit. To audit your store and claim cannabis benefits legally, follow a structured compliance process that aligns every marketing claim with federal and state regulations,
cannabis
The proposed Cannabis Control Board would add $60,000 per year, raising compliance costs by about 30 percent for Pennsylvania cannabis growers. Legal Disclaimer: This content is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for legal matters. Cannabis Control Board Proposal Threatens Growth
cannabis
Cannabis Board vs Hemp Farmers: Pennsylvania Industry Collapse New Pennsylvania regulations are set to push profit margins for local hemp growers below sustainable levels, risking widespread foreclosures. The proposed fee hikes and tighter certification timelines directly threaten the viability of farms that have powered the state’s hemp boom. Legal
cannabis
In 2025, the Treasury estimated that moving cannabis to Schedule II could cut effective federal tax rates by as much as 25% for compliant distributors. The change would lower the excise tax base and unlock new deductions, translating into lower quarterly bills for many operators. Financial Disclaimer: This article is
cannabis
In 2025, compliance costs rose 18% for cannabis operators after Curaleaf faced a $5 million fine. The lawsuit sharpens regulatory scrutiny, forcing payors and clinicians to rethink budget allocations for medical cannabis. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a